| 28.34 1.84 (6.94%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 35 | 1-year : | 37.91 |
| Resists | First : | 29.97 | Second : | 32.45 |
| Pivot price | 29.08 |
|||
| Supports | First : | 25.95 | Second : | 21.59 |
| MAs | MA(5) : | 27 |
MA(20) : | 28.57 |
| MA(100) : | 28.68 |
MA(250) : | 26.63 |
|
| MACD | MACD : | -0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 15.9 |
D(3) : | 11.2 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 39.7 | Low : | 13.69 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ASMB ] has closed above bottom band by 39.6%. Bollinger Bands are 50.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.94 - 32.1 | 32.1 - 32.24 |
| Low: | 27.46 - 27.62 | 27.62 - 27.76 |
| Close: | 28.08 - 28.34 | 28.34 - 28.58 |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Fri, 22 May 2026
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan
Fri, 22 May 2026
Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK
Fri, 22 May 2026
Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus
Fri, 22 May 2026
Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus
Fri, 22 May 2026
Assembly Biosciences prices $100M equity offering - MSN
Fri, 22 May 2026
Assembly Bio (NASDAQ: ASMB) plans Phase 2 ABI-6250 trials in HDV, PBC and PSC - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 32.3 (%) |
| Held by Institutions | 60.2 (%) |
| Shares Short | 1,560 (K) |
| Shares Short P.Month | 1,530 (K) |
| EPS | 0.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.5 |
| Profit Margin | -9 % |
| Operating Margin | -138.5 % |
| Return on Assets (ttm) | -5.1 % |
| Return on Equity (ttm) | -5.7 % |
| Qtrly Rev. Growth | -12.9 % |
| Gross Profit (p.s.) | 0.39 |
| Sales Per Share | 4.47 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 354.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.26 |
| Price to Sales | 6.33 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|